Status:
COMPLETED
Serotonin 1A Agonists and Cognition in Schizophrenia
Lead Sponsor:
Northwestern University
Collaborating Sponsors:
National Alliance for Research on Schizophrenia and Depression
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
Examines cognitive functioning in patients with schizophrenia or schizoaffective disorder who have been treated with antipsychotic medications. Patients will be assigned to take active medication (Bus...
Detailed Description
Examines cognitive functioning in patients with schizophrenia or schizoaffective disorder who have been treated with olanzapine or risperidone for at least three months randomized to receive adjunctiv...
Eligibility Criteria
Inclusion
- Subjects must meet all of the following criteria to be eligible for participation in the current research study.
- Subjects will be males and females between 18-65 years of age;
- Subjects will have a definite diagnosis by DSM-IV criteria for Schizophrenia or Schizoaffective Disorder;
- The subjects or their legal guardian must sign the informed consent;
- Subjects currently being treated with olanzapine or risperidone for a duration of at least 3 months
Exclusion
- Subjects who are pregnant or lactating
- Subjects who have brain damage and/or neurological disorders
- Subjects who have current substance dependence
- Subjects unable to provide informed consent
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2004
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00178971
Start Date
January 1 2003
End Date
October 1 2004
Last Update
June 7 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Psychiatric Hospital at Vanderbilt
Nashville, Tennessee, United States, 37212